Emcure Pharma gains after Sanand facility gets zero observations from USFDA
The inspection conducted from 30 June 2025 to 08 July 2025 and concluded without issuance of Form 483, indicating zero observations.
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
The company's consolidated net profit jumped 64.1% to Rs 188.96 crore on 19.5% increase in net sales to Rs 2,116.25 crore in Q4 FY25 over Q4 FY24.

Low Price Shares
0 mins read . Dec 18, 2024

Nifty 50 Top 10 Stocks
0 mins read . Dec 18, 2024

Best Stocks in 2025
0 mins read . Dec 18, 2024

Explore our products
Unlimited Trading starting at ₹249 ₹0
Open Trading Account